Treatment Compliance of Multidrug Resistant Tuberculosis in Uzbekistan: Does Practice Follow Policy?

Ruzilya Usmanova, Nargiza Parpieva, Hayk Davtyan, Olga Denisiuk, Jamshid Gadoev, Sevak Alaverdyan, Kostyantyn Dumchev, Irina Liverko and Barno Abdusamatova
Additional contact information
Ruzilya Usmanova: Republican Specialized Scientific-Practical Medical Center of Phthisiology and Pulmonology of the Republic of Uzbekistan, 1 Majlisiy Street, Shayhantahur District, Tashkent 100086, Uzbekistan
Nargiza Parpieva: Republican Specialized Scientific-Practical Medical Center of Phthisiology and Pulmonology of the Republic of Uzbekistan, 1 Majlisiy Street, Shayhantahur District, Tashkent 100086, Uzbekistan
Hayk Davtyan: Tuberculosis Research and Prevention Center, NGO, 38 Apartment, 33 Charents Street, Nor Hachn 2412, Armenia
Olga Denisiuk: Alliance for Public Health, Building 3, 24 Bulvarno-Kudryavska Street, 01601 Kyiv, Ukraine
Jamshid Gadoev: World Health Organization (WHO) Country Office in Uzbekistan, 16 Tarobiy Street, Tashkent 100100, Uzbekistan
Sevak Alaverdyan: Bielefeld Graduate School of Economics and Management (BiGSEM), Bielefeld University, 25 Universitätsstraße, 33615 Bielefeld, Germany
Kostyantyn Dumchev: Ukrainian Institute of Public Health Policy, Biloruska Street, 5, 02000 Kyiv, Ukraine
Irina Liverko: Republican Specialized Scientific-Practical Medical Center of Phthisiology and Pulmonology of the Republic of Uzbekistan, 1 Majlisiy Street, Shayhantahur District, Tashkent 100086, Uzbekistan
Barno Abdusamatova: Department of Protection of Maternity and Childhood of the Ministry of Health, 12 Navoi Street, Shayhantahur District, Tashkent 100011, Uzbekistan

IJERPH, 2021, vol. 18, issue 8, 1-11

Abstract: Compliance with treatment guidelines is essential to achieve successful outcomes in tuberculosis patients. Thus, we assessed if multidrug-resistant tuberculosis treatment practices from 2012–2018 in Uzbekistan were compliant with national guidelines in terms of regimens prescribed, weight-based drug dosages used, and documentation of treatment changes (such as prolongation of intensive phase, change of drugs, and their reasons) in the treatment card and Consilium form. A total of 1481 patients were included. Of them, only 25% received standardized regimens as per guidelines and the remaining received individualized regimens. There was an increasing trend in using standardized regimens from 2% in 2012 to 44% in 2018. Compliance to recommended weight-based drug dosages was observed in 85% of the patients during the intensive phase and 84% in the continuation phase—ranged 71–91% over the years. Prolongation of the intensive phase was done in 42% of patients. The treatment was changed in 44% of patients during the intensive phase and 34% of patients during the continuation phase. The documentation of treatment changes was suboptimal (42–75%) during the initial years (2012–2014); however, it improved significantly during later years (86–100%). Future research should explore reasons for non-compliance so that the quality of patient care can be improved.

Keywords: MDR/RR TB; weight-dosage compliance; national guideline compliance; operational research; SORT IT (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2021
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.mdpi.com/1660-4601/18/8/4071/pdf (application/pdf)
https://www.mdpi.com/1660-4601/18/8/4071/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:18:y:2021:i:8:p:4071-:d:534816

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().